Media & Investors

Media and Investor Information


According to the current position, the second half-year will be considerably better compared with the reporting period. We expect a growth in turnover of approximately 18 % versus the forecast 15 %. On this basis, we will raise the outlook for the operating result to approximately CHF 60 million.

More facts & figures

Coming events

24 May 2018 Media conference and analysts’ presentation of the
annual figures 2017/18
27 June 2018 General Meeting of Shareholders Burgdorf

Investor agenda

Latest News

Ypsomed confirms forecast for the current financial year and looks to the future with confidence

Burgdorf, 07.03.2018, 2.00 p.m. - The guidance of CHF 60 million EBIT for the 2017/18 financial year announced in November 2017 remains unchanged. Ypsomed is investing in its global expansion and the establishment of new subsidiaries for the insulin pump business. Ypsomed expects sustained growth in the Ypsomed Delivery Systems (YDS) segment.

Swisscom and Ypsomed test 5G in production operations for the first time

Swisscom and Ypsomed test 5G in production operations for the first time

Burgdorf, 05.03. 2018, 7.00 a.m. - Swisscom and Ypsomed have been cooperating since the spring of 2017 to develop application options for the latest generation of mobile communications. Ypsomed has digitised selected production processes with 5G. This simplifies processes considerably, makes them even safer and more efficient.

Ypsomed is committed to equal pay

Ypsomed is committed to equal pay

Burgdorf, 23.02.2018, 7.00 a.m. – February 24th marks Equal Pay Day in Switzerland. Ypsomed already had Equal Pay Day on January 18th and is strongly committed to further reduce inequality in pay between men and women. Cross-divisional analyses and individual case studies ensure equal pay in the company over the long term.

Ypsomed is driving the connectivity of its portfolio with digital solutions

Ypsomed is driving the digitisation of its portfolio

Burgdorf, 31.01.2018, 7 a.m. – Ypsomed continues to expand its offers for digital diabetes therapy with the launch of the mylife App. The mylife App is connected to the mylife YpsoPump® insulin pump via Bluetooth® and continuously records current therapy data. Digital therapy solutions add to customer benefit and increase the success of therapy long-term.

Ypsomed grows during first half-year and raises its forecast for the year

Burgdorf, 09.11.2017, 7.00 a.m. – During the first six months of the business year 2017/18, Ypsomed generated a consolidated total turnover of CHF 213.4 million. The growth corresponds to an increase in turnover of 15.1% (previous year: CHF 185.4 million). The net profit for the reporting period amounts to CHF 23.4 million (previous year CHF 22.4 million). The operating result amounts to CHF 26.9 million with an EBIT margin of 12.9 %. Ypsomed expects a growth in turnover of approximately 18% versus the presently forecast 15% and increases the forecast to an operating result of around CHF 60 million for the business year 2017/18.